Interview with Manuel Reiberg, Manager Company Operations, Daiichi Sankyo…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Address: Effingergasse 21, 1160 Vienna,Austria
Tel: +43 1 48586420
Web: http://www.daiichi-sankyo.at/
Daiichi Sankyo Austria GmbH is the Austrian affiliate of Daiichi Sankyo, a global pharmaceutical company that focuses on researching and marketing innovative medications. The company’s roots extend back to 1899 and the early days of industrialization of the pharmaceutical sector.
The company itself was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €8.6 billion in fiscal year 2011, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company does business in nearly 60 countries around the world. Daiichi Sankyo’s world headquarters are in Tokyo, Japan.
The company’s roots in Europe extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. The company currently does business in 12 European countries including Austria. With nearly 2,500 employees, Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe.
Striving for innovation is a central task of Daiichi Sankyo. Innovation is the fundamental requirement for achieving the corporate goal of developing pharmaceutical products that are the best in their class or for establishing a new class of active ingredients. Furthermore, the commitment to fulfill or exceed the high expectations of stakeholders regarding corporate services, information and organizational processes is based on innovation as a fundamental principle.
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of doctors and patients. In its research, the company aims to develop drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for patients with thrombotic disorders and is focused on the discovery of novel oncology and cardiovascular-metabolic therapies.egulations. Detailed information about such drugs, such as the performance of our products may be provided only to medical professionals. For this reason, we can only give you an overview of our main products.
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the…
Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
Dr. Sabine Mӧritz-Kaisergruber and Helmut Kaisergruber, CEOs of Astro Pharma, a young vibrant Austrian pharmaceutical company, discuss their tailored strategy to establish themselves within the Austrian market as well as…
Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian…
Siegfried Leitner, general manager of Accord Austria and Germany, and CEO and co-founder of A-med, provides an insight into the early years of his Accord affiliate and how it was…
Robert Sauermann, head of the department of pharmaceutical affairs in the Main Association of Austrian Social Security Institutions, which publishes the national code of reimbursement, provides an in-depth look into…
Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market…
Martin Peithner, CEO of Dr. Peithner and Austroplant, two leading medical companies focusing on homeopathic and herbal medicines in Austria, discusses the evolution of the companies over the last five…
Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct…
Eva Bano, CEO of BANO, an exciting west Austrian company, discusses the company’s modern revamp and expansion from natural therapies to pharmaceutical products. She also explains the importance of a…
Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the…
See our Cookie Privacy Policy Here